ライフサイエンスコーパス: adenocarcinoma

1 d prevented progression to invasive prostate adenocarcinoma.

2 al analyses were conducted for patients with adenocarcinoma.

3 ates with poor outcome of patients with lung adenocarcinoma.

4 cantly different between populations in lung adenocarcinoma.

5 22 had high-grade dysplasia or intramucosal adenocarcinoma.

6 e a strong negative prognostic value in lung adenocarcinoma.

7 ssociated with the risk of gastric noncardia adenocarcinoma.

8 er overall and six loci associated with lung adenocarcinoma.

9 Notch has a synergistic effect in esophageal adenocarcinoma.

10 ion for liver-dominant metastatic colorectal adenocarcinoma.

11 ecursor to intestinal metaplasia and gastric adenocarcinoma.

12 ival compared with typical pancreatic ductal adenocarcinoma.

13 apy and pancreatectomy for pancreatic ductal adenocarcinoma.

14 amming is an emerging hallmark of pancreatic adenocarcinoma.

15 ative of the genomic landscape of esophageal adenocarcinoma.

16 ntly overexpressed in SCLC, compared to lung adenocarcinoma.

17 or patients with resectable oesophagogastric adenocarcinoma.

18 herapy-for early-stage resectable pancreatic adenocarcinoma.

19 s who had undergone resection for pancreatic adenocarcinoma.

20 rect attribution for KB, as HeLa or cervical adenocarcinoma.

21 rade and poor survival in patients with lung adenocarcinoma.

22 KRAS gene mutation causes lung adenocarcinoma.

23 nical stage I or II resected pancreatic head adenocarcinoma.

24 patients (0.9%) developed a distinct ductal adenocarcinoma.

25 itive gastric or gastro-oesophageal junction adenocarcinoma.

26 ntly higher levels in SCLC, compared to lung adenocarcinoma.

27 ble patients with resected pancreatic ductal adenocarcinoma.

28 re following resection for pancreatic ductal adenocarcinoma.

29 racial groups in five cancers, such as lung adenocarcinoma.

30 tion and transcript were most common in lung adenocarcinoma.

31 e strongest known risk factor for esophageal adenocarcinoma.

32 c factor for patients with pancreatic ductal adenocarcinoma.

33 ion of clinically-relevant mutations in lung adenocarcinoma.

34 al after resection of pancreatic-head ductal adenocarcinoma.

35 ruvate metabolism, is downregulated in colon adenocarcinomas.

36 nesis of cancers such as lung and pancreatic adenocarcinomas.

37 breast, endometrial, pancreas, or colorectal adenocarcinomas.

38 location of Thy-1(+) CAFs within human lung adenocarcinomas.

39 ures in CT images of 258 non-small cell lung adenocarcinomas.

40 phenotype in patients with KRAS mutant lung adenocarcinomas.

41 progression when activated in advanced lung adenocarcinomas.

42 uctal papillary mucinous neoplasms (IPMN), 2 adenocarcinomas, 1 low-grade intraepithelial pancreatic

43 erall, 509 lung cancer tumors specimens (319 adenocarcinomas; 142 squamous cell carcinomas) were prof

44 3592 patients with esophageal cancer (84.7% adenocarcinoma, 15.2% squamous cell carcinoma), 335 (9.3

45 In the 44 patients with adenocarcinoma, 41 (93.2%) had lymph nodes harvested, wi

46 and time-dependent progression of CRCs from adenocarcinoma (6 weeks), to local disseminated disease

47 al phenotype of ADAR1 deletion in human lung adenocarcinoma A549 cells is rescued by CRISPR/Cas9 muta

48 vel of expression of miR-155 in a human lung adenocarcinoma A549R cell line that is highly resistant

49 expression), 1023 NSCLC cases-519 from TCGA adenocarcinoma (AD) project and 504 from TCGA squamous c

50 Adenocarcinoma (ADC) and squamous cell carcinoma (SqCC)

51 expected diffusion characteristics included: adenocarcinoma, adenoid cystic carcinoma, meningioma, ch

52 zed, and their inhibitory effects on gastric adenocarcinoma (AGS) and esophageal squamous cell carcin

53 tatic gastric or gastro-oesophageal junction adenocarcinoma, an Eastern Cooperative Oncology Group (E

54 eatment of advanced or metastatic pancreatic adenocarcinoma and advanced epithelial ovarian cancer.

55 take was seen in one subject with pancreatic adenocarcinoma and another with liver cancer.

56 e exon 14 splice sites are recurrent in lung adenocarcinoma and cause exon skipping (METDelta14).

57 ristics of six cases containing both gastric adenocarcinoma and GIST.

58 infection in two human cell lines: A549 lung adenocarcinoma and HuH-7 hepatoma cells, and for product

59 nt study was 12 months, and those with NSCLC-adenocarcinoma and Lung-molGPA scores of 3.5 to 4.0 had

60 Using 313 adenocarcinomas and 138 squamous cell carcinomas with ge

61 ression of miR-487b-3p is decreased in colon adenocarcinomas and inversely correlates with GRM3 expre

62 effective neoadjuvant CRT regimens for both adenocarcinomas and squamous cell carcinomas of the esop

63 al adenocarcinoma), HT29-MTX-E12 (colorectal adenocarcinoma) and HepG2 (hepatocellular carcinoma), we

64 e cytosol in U251 (glioblastoma), A549 (lung adenocarcinoma) and MDA-MB-231(breast cancer).

65 istological type (squamous cell carcinoma vs adenocarcinoma) and type of neoadjuvant treatment (chemo

66 ioblastoma, astrocytoma, neuroblastoma, lung adenocarcinoma, and breast cancer.

67 ncluding respiratory distress syndrome, lung adenocarcinoma, and debilitating fibrotic diseases, but

68 s of renal cell carcinoma, pancreatic ductal adenocarcinoma, and melanoma triggered RagD-mediated mTO

69 11 loss results in degradation of Pten, lung adenocarcinoma, and neoplasia in mouse prostate with abe

70 ion correlates with worse prognosis for lung adenocarcinoma, and that a three-gene expression signatu

71 primate frontal cortex tissue and two human adenocarcinomas, and obtained a detailed assessment of s

72 Mucinous cystic neoplasm-associated adenocarcinoma appears to have decreased nodal involveme

73 tion and dominant-negative activity) in lung adenocarcinoma are unclear.

74 Pulmonary adenocarcinomas are frequently associated with an activa

75 Ovarian adenocarcinomas are shown to be an excellent model for d

76 We use pancreatic ductal adenocarcinoma as an in vitro and an in vivo cancer mode

77 mposition is fundamentally different in lung adenocarcinoma as compared with lung squamous cell carci

78 e formation of aggressive metastatic mammary adenocarcinoma at 9-16 months of age.

79 gastrectomy for stage I through III gastric adenocarcinoma between 2009 and 2012.

80 510) who underwent pancreatoduodenectomy for adenocarcinoma between January 1995 and December 2014.

81 urative-intent total gastrectomy for gastric adenocarcinoma between January 2009 and December 2012 an

82 t GalNAc-T6 was highly up-regulated in colon adenocarcinomas but absent in normal-appearing adjacent

83 g genes are frequently mutated in human lung adenocarcinoma, but the functional impact of these mutat

84 5, 1.17; P for trend = 0.09), especially for adenocarcinomas, but not with poultry or pig farming.

85 Braf allele prevents the development of lung adenocarcinoma by inducing a further increase in MAPK si

86 nts, oncogenic KRAS plays a critical role in adenocarcinomas by promoting PI3K/Akt signaling.

87 a lower risk of developing gastric noncardia adenocarcinoma [C3 compared with C0, HR: 0.73 (95% CI: 0

88 g recalcitrant tumors like pancreatic ductal adenocarcinoma, cause off-target toxicities in normal, h

89 asion and replication assays with human lung adenocarcinoma cell line A549.

90 ly enhanced potency against three esophageal adenocarcinoma cell lines compared with the two homo-pro

91 liver CO to a suspension of human colorectal adenocarcinoma cells (HT-29) under the control of visibl

92 cancer effect of PSM and PSB over pancreatic adenocarcinoma cells and glioblastoma cells.

93 uroendocrine (NE) cells arises from prostate adenocarcinoma cells are poorly understood.

94 ated that breast cancer cells and pancreatic adenocarcinoma cells generated micromolar level H2O2 dur

95 In contrast, PD-L1 on MC38 colorectal adenocarcinoma cells is sufficient to suppress antitumor

96 eatment in a xenograft model using A549 lung adenocarcinoma cells resulted in decreased tumor volume

97 r-induced BTP using female rats with mammary adenocarcinoma cells sealed within the tibia.

98 ibited the proliferation of DLD-1 colorectal adenocarcinoma cells to a greater extent than 1.

99 VGF silencing resensitized EGFR-mutated lung adenocarcinoma cells to TKI.

100 HT-29 colon adenocarcinoma cells were formed into pellets and covere

101 -sensitive and cisplatin-resistant A549-lung adenocarcinoma cells.

102 and murine SCLC cell lines, but not in lung adenocarcinoma cells.

103 ients with surgically resectable oesophageal adenocarcinoma classified as stage cT1N1, cT2N1, cT3N0/N

104 as(LA1)), here we postulated that human lung adenocarcinomas containing Thy-1(+) CAFs have a worse pr

105 e, SIN3B was downregulated in human prostate adenocarcinoma correlating with upregulation of its targ

106 In the case of colorectal adenocarcinoma (CRA), grading is partly determined by mo

107 h risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated superior survival for patie

108 with histologically confirmed primary colon adenocarcinoma diagnosed between 1998 and 2007.

109 Bacteria may play a role in esophageal adenocarcinoma (EAC) and esophageal squamous cell carcin

110 5 (TGR5) were highly expressed in esophageal adenocarcinoma (EAC) and precancerous lesions.

111 sk of Barrett's esophagus (BE) or esophageal adenocarcinoma (EAC) based on genetic and non-genetic fa

112 anisms that mediate resistance of esophageal adenocarcinoma (EAC) cells and patient-derived xenograft

113 The incidence of esophageal adenocarcinoma (EAC) has increased in many Western count

114 to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) in patients with LGD of the esophag

115 Esophageal adenocarcinoma (EAC) is a highly lethal cancer with limi

116 The incidence of esophageal adenocarcinoma (EAC) is rapidly rising in the United Sta

117 has become a standard of care for esophageal adenocarcinoma (EAC).

118 of high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC).

119 to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC).

120 representing HER2 overexpressing esophageal adenocarcinomas (EACs) and EGFR overexpressing esophagea

121 esophagitis, Barrett's esophagus, esophageal adenocarcinoma, erosive gastritis, gastric cancer, diarr

122 peanut butter and the risk of gastric cardia adenocarcinoma, esophageal adenocarcinoma, or esophageal

123 Pancreatic ductal adenocarcinoma, even when diagnosed early, nearly always

124 protein that is highly expressed on prostate adenocarcinomas, exhibits only limited expression in ben

125 vival in patients with metastatic pancreatic adenocarcinoma for whom gemcitabine-based chemotherapy h

126 014, 137 patients with metastatic pancreatic adenocarcinoma for whom gemcitabine-based chemotherapy h

127 ogically proven, resectable oesophagogastric adenocarcinoma from 87 UK hospitals and cancer centres.

128 n 17600 patients with stage II to III rectal adenocarcinoma from the 2006-2012 National Cancer Databa

129 ) with newly diagnosed metastatic pancreatic adenocarcinoma from the Comprehensive Cancer Center of W

130 ssion is dramatically down-regulated in lung adenocarcinomas from lung cancer patients, both at the m

131 cluding hepatocellular carcinoma and ovarian adenocarcinoma, Gadd45b inhibition in myeloid cells rest

132 for patients with advanced gastroesophageal adenocarcinoma (GEA).

133 HUH7, as well as in liver tumors, esophageal adenocarcinoma, glioblastoma multiforme, prostate tumors

134 inal-type duodenal, ampullary, or distal CBD adenocarcinomas had longer median overall survival than

135 Esophageal adenocarcinomas have mutations in tumor protein p53 and

136 Younger age, central location, adenocarcinoma histology, and higher positron emission t

137 y three human cell lines, Caco-2 (colorectal adenocarcinoma), HT29-MTX-E12 (colorectal adenocarcinoma

138 of the orthologous mouse allele induced lung adenocarcinoma in a novel, immunocompetent mouse model.

139 he catalogue of regions associated with lung adenocarcinoma in non-smoking Asian women and highlight

140 cal intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ (cervical intraepithelial neoplas

141 ical intraepithelial neoplasia grade 2 or 3, adenocarcinoma in situ, invasive cervical carcinoma), vu

142 that the behavior and management of IPMN and adenocarcinoma in the pancreas graft appears congruent t

143 he human BRAF(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivatin

144 nited States, while disparities increased in adenocarcinoma incidence as measured on the absolute sca

145 mice and cancer patients (n = 70) that lung adenocarcinomas increase bone stromal activity in the ab

146 (Brg1) or Arid1a had complex effects on lung adenocarcinoma initiation and progression.

147 tion of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial o

148 nable distinction between invasive pulmonary adenocarcinomas (IPAs) and pre-invasive lesions.

149 Pancreatic ductal adenocarcinoma is a notoriously difficult-to-treat cance

150 Purpose Metastatic pancreatic ductal adenocarcinoma is characterized by excessive hyaluronan

151 Surgical management for rectal adenocarcinoma is evolving towards utilization of LP and

152 Pancreatic adenocarcinoma is moderately responsive to gemcitabine-b

153 Esophageal adenocarcinoma is more frequent in non-Hispanic whites,

154 Gastric adenocarcinoma is the third leading cause of cancer-rela

155 oncogenic event in almost half of human lung adenocarcinomas is still unknown, a fact that complicate

156 g preoperative therapy for pancreatic ductal adenocarcinoma, it is associated with a significantly im

157 in a murine model of Kras(G12D)-driven lung adenocarcinoma (Kras(LA1)), here we postulated that huma

158 We show that stage I lung adenocarcinoma lesions already harbor significantly alte

159 d from normal rectal mucosa (control) and an adenocarcinoma line derived from a patient with germline

160 In clinical specimens of lung adenocarcinoma, low KLF10 expression associated with dec

161 c gene mutation rate difference between lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (

162 trends in predicting poor prognosis in lung adenocarcinoma (LUAD) but not in lung squamous cell carc

163 Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cance

164 has been reported to contribute lung cancer adenocarcinoma (LUAD), but the mechanisms are unclear.

165 the ion channel TRPA1 is implicated in lung adenocarcinoma (LUAD), where its role and mechanism of a

166 mpact of 19 well-defined DCAFs in human lung adenocarcinomas (LuADCs) using integrative omics analyse

167 ting cancer cell invasive phenotypes in lung adenocarcinoma, lung squamous cell carcinoma and breast

168 nsition to highly proliferative and invasive adenocarcinomas marked by highly inflammatory, angiogeni

169 model that recapitulates the entire adenoma-adenocarcinoma-metastasis axis in vivo.

170 migration and metastasis in EMT-driven lung adenocarcinoma models.

171 In transgenic adenocarcinoma mouse prostate model, Skp2 depletion lead

172 s: EGFR and ALK alterations in patients with adenocarcinoma (mutation status was not routinely tested

173 on of D2 dopamine (DA) receptors in CD133+ve adenocarcinoma NSCLC cells.

174 Oesophageal adenocarcinoma (OAC) is increasing in incidence and has

175 serving surgery for unifocal invasive ductal adenocarcinoma of grade 1-3, with a tumour size of 3 cm

176 low- and high-grade tumors in the transgenic adenocarcinoma of mouse prostate (TRAMP) transgenic mous

177 ced, or metastatic gastric cancer, including adenocarcinoma of the gastro-oesophageal junction).

178 tients with resected, clinical stage I or II adenocarcinoma of the head of the pancreas were identifi

179 onsecutive patients with potentially curable adenocarcinoma of the lower esophagus or gastroesophagea

180 tment disease-free survival of patients with adenocarcinoma of the lung.

181 mors of the prostate cancer-prone transgenic adenocarcinoma of the mouse prostate (TRAMP) mice result

182 a patient population confined to people with adenocarcinomas of the oesophagus and gastro-oesophageal

183 defined as high-grade dysplasia or invasive adenocarcinoma on results of surgical pathologic evaluat

184 group as well as the TP53/EGFR comutation in adenocarcinoma only through a multivariable Cox proporti

185 Adenocarcinoma or high-grade dysplasia is present in 14.

186 of gastric cardia adenocarcinoma, esophageal adenocarcinoma, or esophageal squamous cell carcinoma.Am

187 tudy, 1122 participants developed pancreatic adenocarcinoma over 4.2 million person-years.

188 may shed light into normal biology and lung adenocarcinoma pathogenesis, and be valuable for discove

189 a Base was queried for T1-3N0-1M0 pancreatic adenocarcinoma patients who underwent PD.

190 SPOP) is frequently dysregulated in prostate adenocarcinoma (PC), via either somatic mutations or mRN

191 y 50% of all patients with pancreatic ductal adenocarcinoma (PDA) develop diabetes mellitus before th

192 Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer that resists eff

193 microenvironment (TME) in pancreatic ductal adenocarcinoma (PDA) is characterized by immune toleranc

194 Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human mal

195 mprove the poor outcome of pancreatic ductal adenocarcinoma (PDA).

196 stablished risk factor for pancreatic ductal adenocarcinoma (PDA).

197 t the distal tumor site of pancreatic ductal adenocarcinoma (PDAC) ablated the development of salivar

198 Pancreatic ductal adenocarcinoma (PDAC) after complete surgical resection

199 is aberrantly expressed in pancreatic ductal adenocarcinoma (PDAC) and generally correlates with incr

200 regulated in patients with pancreatic ductal adenocarcinoma (PDAC) and in obese individuals, but whet

201 and prolonged survival in pancreatic ductal adenocarcinoma (PDAC) and our genomic analysis revealed

202 ark genetic alterations in pancreatic ductal adenocarcinoma (PDAC) and the key drivers of its initiat

203 ships between diabetes and pancreatic ductal adenocarcinoma (PDAC) are complex.

204 Early-detection tests for pancreatic ductal adenocarcinoma (PDAC) are needed.

205 promote the development of pancreatic ductal adenocarcinoma (PDAC) are poorly defined.

206 Pancreatic ductal adenocarcinoma (PDAC) cells (PCC) have an exceptional pr

207 r discharging lactate from pancreatic ductal adenocarcinoma (PDAC) cells.

208 atitis virus (VSV) against pancreatic ductal adenocarcinoma (PDAC) cells.

209 tasis, which in turn makes pancreatic ductal adenocarcinoma (PDAC) difficult to treat, especially the

210 The genome of pancreatic ductal adenocarcinoma (PDAC) frequently contains deletions of t

211 Pancreatic ductal adenocarcinoma (PDAC) has generally a poor prognosis, bu

212 Pancreatic ductal adenocarcinoma (PDAC) has single-digit 5-year survival r

213 Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and disseminati

214 Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive malignancy charac

215 Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a

216 Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive stro

217 Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignanci

218 mic cancer therapeutics in pancreatic ductal adenocarcinoma (PDAC) is partly attributed to deposition

219 ontogeny of TAMs in murine pancreatic ductal adenocarcinoma (PDAC) models.

220 phages in a mouse model of pancreatic ductal adenocarcinoma (PDAC) originate from both the yolk sac (

221 cancer cells derived from pancreatic ductal adenocarcinoma (PDAC) PAR2 protein is necessary for TGF-

222 rchitecture contributes to pancreatic ductal adenocarcinoma (PDAC) phenotypes.

223 Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal disease in

224 mages of multiplex-labeled pancreatic ductal adenocarcinoma (PDAC) tissue samples.

225 the survival prospects of pancreatic ductal adenocarcinoma (PDAC), additional engagement of the immu

226 ene KRAS are a hallmark of pancreatic ductal adenocarcinoma (PDAC), an aggressive malignancy with few

227 (PC) including the most common type, ductal adenocarcinoma (PDAC), but its role and the mechanisms i

228 nhanced drug uptake and effect in pancreatic adenocarcinoma (PDAC), notorious for having poor respons

229 chemotherapy resistance in pancreatic ductal adenocarcinoma (PDAC).

230 ely become fully malignant pancreatic ductal adenocarcinoma (PDAC).

231 d in many tumors including pancreatic ductal adenocarcinoma (PDAC).

232 susceptibility factor for pancreatic ductal adenocarcinoma (PDAC).

233 as (PanINs) and ultimately pancreatic ductal adenocarcinoma (PDAC).

234 assisted approach, 24% for pancreatic ductal adenocarcinoma (PDAC).

235 shown to be deregulated in pancreatic ductal adenocarcinoma (PDAC).

236 on are required to develop pancreatic ductal adenocarcinoma (PDAC).

237 nt treatment of resectable pancreatic ductal adenocarcinoma (PDAC).

238 , is a puzzling feature of pancreatic ductal adenocarcinoma (PDACs).

239 d in a small proportion of pancreatic ductal adenocarcinomas (PDACs).

240 KRAS are detected in most pancreatic ductal adenocarcinomas (PDACs).

241 ions that can develop into pancreatic ductal adenocarcinomas (PDACs).

242 ncoding alterations in 308 pancreatic ductal adenocarcinomas (PDAs) and identify commonly mutated reg

243 tion of gastric or gastroesophageal junction adenocarcinoma, postoperative chemoradiotherapy using a

244 correlation of LSD1 overexpression with lung adenocarcinoma progression and metastasis.

245 To study the regulation of colorectal adenocarcinoma progression by O-GlcNAc, we have focused

246 of the microenvironment to lung fibrosis and adenocarcinoma progression, two pathologies characterize

247 ssor function for SIN3B that limits prostate adenocarcinoma progression, with potential implications

248 Expression profiling of 182 cases of lung adenocarcinoma proved a significant correlation of LSD1

249 The adenocarcinoma rate rose among non-Hispanic whites and a

250 Adenocarcinoma recurred in 11 patients (25%), with a 64%

251 ing between indolent and aggressive prostate adenocarcinoma remains a priority to accurately identify

252 ntestine, and that invasive ARID1A-deficient adenocarcinomas resemble human colorectal cancer (CRC).

253 Whole-genome sequencing analysis of lung adenocarcinomas revealed noncoding somatic mutational ho

254 neuroendocrine markers in pancreatic ductal adenocarcinoma, revealing heterogeneous expression of th

255 ssociations by EGFR mutation status for lung adenocarcinoma risk among never-smoking Asian women, we

256 rs7216064 (17q24.3, BPTF), for overall lung adenocarcinoma risk, and rs3817963 (6p21.3, BTNL2) which

257 ge difference and between-group variance-for adenocarcinoma rose by 3.2% and 6.8% per year, respectiv

258 dings, immunohistochemistry analysis of lung adenocarcinoma samples showed that expression levels of

259 lso found in vivo in a large dataset of lung adenocarcinoma samples.

260 Small-bowel adenocarcinomas (SBAs) are rare cancers with a significa

261 adiogenomic analysis of prostate glands with adenocarcinoma shows a continuum of mutations across reg

262 beta3 axis, was also detected in human lung adenocarcinoma specimens.

263 es (SSN) <==3 cm diagnosed pathologically as adenocarcinoma spectrum to investigate whether parameter

264 f EGFR mutations in pulmonary nodules of the adenocarcinoma spectrum.

265 3/KRAS comutation in all patients and in the adenocarcinoma subgroup as well as the TP53/EGFR comutat

266 ffers a valuable tool to investigate gastric adenocarcinoma subtypes where RAS/MAPK pathway activatio

267 copic surgery among 471 patients with rectal adenocarcinoma suitable for curative resection conducted

268 Among patients with rectal adenocarcinoma suitable for curative resection, robotic-

269 F-15 in epithelial ducts of human pancreatic adenocarcinoma supports the importance of this observati

270 iation of XPC rs2229090 was more apparent in adenocarcinoma than in squamous cell carcinoma patients.

271 nriched tumors in a compendium of 1,586 lung adenocarcinomas, the presence of the 425-gene signature

272 aracterization in six patients with prostate adenocarcinoma (three patients, Gleason score of 3 + 4;

273 loss or reduced expression of IL-37 in lung adenocarcinoma tissues was significantly associated with

274 Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a broadly expres

275 ing RNA (lncRNA), metastasis-associated lung adenocarcinoma transcript 1 (Malat1), in ischemic stroke

276 enetically engineered mouse model of gastric adenocarcinoma tumorigenesis based on Kras(G12D) express

277 Finally, animals with subcutaneous R3230 adenocarcinoma tumors were allocated to RFA or sham trea

278 classes and to compare overall survival for adenocarcinoma vs nonadenocarcinoma groups.

279 having high-grade dysplasia or intramucosal adenocarcinoma was 0% (0-4).

280 Median follow-up for patients with adenocarcinoma was 27 months.

281 having high-grade dysplasia or intramucosal adenocarcinoma was 87% (73-95).

282 r types and single-cell RNA-seq data of lung adenocarcinoma, we confirmed an anticorrelation between

283 ic resection specimens from 10 patients with adenocarcinoma, we found normal zymogenic chief cells th

284 Three fragments from a single rectal adenocarcinoma were chosen for whole-exome sequencing fo

285 rectal resections for stage I to III rectal adenocarcinoma were included from the National Cancer Da

286 n an autochthonous mouse model of pancreatic adenocarcinoma-whereas conditional knockout of another R

287 ophagus is the main precursor to oesophageal adenocarcinoma, which has a poor prognosis.

288 (NTR1) is overexpressed in ductal pancreatic adenocarcinoma, which is still one of the deadliest canc

289 were apparent in all histologic types except adenocarcinoma, which is the type less related to smokin

290 ix patients with confirmed ductal pancreatic adenocarcinoma who had exhausted all other treatment opt

291 topathologically confirmed pancreatic ductal adenocarcinoma who received preoperative therapy prior t

292 queried for patients with pT2/T3 gallbladder adenocarcinoma who underwent resection.

293 rials and Methods Six patients with prostate adenocarcinoma who underwent robotic prostatectomy with

294 ically confirmed stage IIIB or stage IV lung adenocarcinoma with a confirmed, activating EGFR mutatio

295 portant in both cases of synchronous gastric adenocarcinoma with GIST and GIST alone.

296 The biopsy specimen revealed adenocarcinoma with no actionable mutations present.

297 CD34 and Dog1 in all six synchronous gastric adenocarcinomas with GIST, and in GIST alone.

298 Regarding cases with adenocarcinoma within IP, some experts recommend to rout

299 tive change in elastic modulus in colorectal adenocarcinoma xenograft models in vivo and investigate

300 ori is the strongest risk factor for gastric adenocarcinoma, yet only a minority of infected persons